Bionime Management
Management criteria checks 2/4
Bionime's CEO is Roy Huang, appointed in Jan 2002, has a tenure of 23.08 years. directly owns 5.95% of the company’s shares, worth NT$242.19M. The average tenure of the management team and the board of directors is 6.3 years and 3.1 years respectively.
Key information
Roy Huang
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 23.1yrs |
CEO ownership | 5.9% |
Management average tenure | 6.3yrs |
Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2
Jul 22Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year
Jul 01These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong
Apr 29Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?
Mar 23Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?
Mar 05Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?
Feb 15Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet
Feb 01How Has Bionime (TPE:4737) Allocated Its Capital?
Jan 19A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE
Jan 06A Look At The Fair Value Of Bionime Corporation (TPE:4737)
Dec 22Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend
Dec 09Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment
Nov 24CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -NT$83m |
Jun 30 2024 | n/a | n/a | -NT$40m |
Mar 31 2024 | n/a | n/a | NT$7m |
Dec 31 2023 | n/a | n/a | NT$6m |
Sep 30 2023 | n/a | n/a | NT$22m |
Jun 30 2023 | n/a | n/a | NT$43m |
Mar 31 2023 | n/a | n/a | NT$72m |
Dec 31 2022 | n/a | n/a | NT$91m |
Sep 30 2022 | n/a | n/a | NT$95m |
Jun 30 2022 | n/a | n/a | NT$115m |
Mar 31 2022 | n/a | n/a | NT$89m |
Dec 31 2021 | NT$4m | NT$4m | NT$87m |
Sep 30 2021 | n/a | n/a | NT$101m |
Jun 30 2021 | n/a | n/a | NT$111m |
Mar 31 2021 | n/a | n/a | NT$83m |
Dec 31 2020 | NT$4m | NT$4m | NT$62m |
Sep 30 2020 | n/a | n/a | NT$73m |
Jun 30 2020 | n/a | n/a | NT$38m |
Mar 31 2020 | n/a | n/a | NT$91m |
Dec 31 2019 | NT$5m | NT$4m | NT$106m |
Compensation vs Market: Insufficient data to establish whether Roy's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Roy's compensation has increased whilst the company is unprofitable.
CEO
Roy Huang
23.1yrs
Tenure
NT$4,429,000
Compensation
Mr. Chun-Mu Huang also known as Roy, founded Bionime Corporation in 2002. Mr. Huang serves as Chairman and General Manager of Bionime Corporation and has been its Director since April 14, 2003. He Complete...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 23.1yrs | NT$4.43m | 5.95% NT$ 242.2m | |
Manager of Human Resources Department & Financial Officer | less than a year | no data | no data | |
Assistant General Manager of Operation Division | 9yrs | no data | no data | |
Assistant GM of Administration Division & Corporate Governance Officer | 1.8yrs | no data | no data | |
Vice President of Research and Development | no data | no data | no data | |
Assistant General Manager of Sales Division | 6.3yrs | no data | no data | |
Assistant General Manager of Marketing Planning Division | 6.3yrs | no data | no data |
6.3yrs
Average Tenure
Experienced Management: 4737's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 21.8yrs | NT$4.43m | 5.95% NT$ 242.2m | |
Representative Director | 5.7yrs | NT$533.00k | no data | |
Representative Director | 3yrs | no data | no data | |
Independent Director | no data | no data | no data | |
Independent Director | no data | no data | 0.16% NT$ 6.4m | |
Independent Director | no data | no data | 0.048% NT$ 1.9m | |
Director | 3.1yrs | no data | no data | |
Additional Independent Director | 1.7yrs | no data | 0.45% NT$ 18.1m |
3.1yrs
Average Tenure
Experienced Board: 4737's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 12:08 |
End of Day Share Price | 2025/01/22 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bionime Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ryan Liu | IBTS Investment Consulting Co., Ltd. |
Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
Hsiu Chi Lin | Masterlink Securities Corp. |